CNBCLean R·
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Read at CNBC →
Business · 1 sources covering this
Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/e425214bc6154472d6a775a4fba515def0cf63ba" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength"></iframe>
